<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965402</url>
  </required_header>
  <id_info>
    <org_study_id>IM018-007</org_study_id>
    <nct_id>NCT04965402</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug&#xD;
      effects of BMS-986166 in healthy Japanese male and female participants of non-childbearing&#xD;
      potential.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 9, 2021</start_date>
  <completion_date type="Anticipated">November 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of BMS-986166: Maximum observed blood concentration (Cmax)</measure>
    <time_frame>Day 1, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of BMS-986166: Time of maximum observed blood concentration (Tmax)</measure>
    <time_frame>Day 1, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of BMS-986166: Area under the concentration-time curve within a dosing interval (AUC(TAU))</measure>
    <time_frame>Day 1, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of BMT-121795: Cmax</measure>
    <time_frame>Day 1, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of BMT-121795: Tmax</measure>
    <time_frame>Day 1, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of BMT-121795: AUC(TAU)</measure>
    <time_frame>Day 1, Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all adverse events (AEs)</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of all AEs</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of all AEs</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence serious adverse events (SAEs)</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of all SAEs</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of all SAEs</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of all AEs regardless of seriousness criteria</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator causality assessment of all AEs regardless of seriousness criteria</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes of all AEs regardless of seriousness criteria</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in physical examination findings</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 77 days</time_frame>
    <description>PR interval: The time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QRS interval</measure>
    <time_frame>Up to 77 days</time_frame>
    <description>QRS interval: A combination of the Q wave, R wave and S wave, the &quot;QRS complex&quot; represents ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QT interval</measure>
    <time_frame>Up to 77 days</time_frame>
    <description>QT interval: Measured from the beginning of the QRS complex to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QTcF interval</measure>
    <time_frame>Up to 77 days</time_frame>
    <description>QTcF interval: Corrected QT interval using Fridericia's formula (QTcF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in continuous cardiac monitoring data</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in ECG parameters: QRS interval</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in ECG parameters: QT interval</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in ECG parameters: QTcF interval</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in continuous cardiac monitoring data</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in vital signs: Body temperature</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in vital signs: Respiratory rate</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in vital signs: Blood pressure</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in vital signs: Heart rate</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline values in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Panel 1: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986166</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Panel 1: Dose 1</arm_group_label>
    <arm_group_label>Panel 2: Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese (both biological parents are ethnically Japanese)&#xD;
&#xD;
          -  Healthy as determined by medical history, physical examination, vital signs, 12-lead&#xD;
             electrocardiograms (ECGs), and clinical laboratory evaluations&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18.0 to 32.0 kg/m^2, inclusive. BMI = weight (kg)/(height&#xD;
             [m])^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant acute or chronic medical illness judged to be clinically significant by&#xD;
             the investigator and/or Sponsor's medical monitor&#xD;
&#xD;
          -  History of heart disease, retinopathy, uveitis, other clinically significant ocular&#xD;
             disease, gastrointestinal disease, stroke or transient ischemic attacks (TIA)&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  Women who are of childbearing potential, breastfeeding, or lactating&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986166</keyword>
  <keyword>Japan</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

